Puma Biotechnology is a Los Angeles oncology company that just finished paying off its last term loan and is asking the market to treat a reaccelerating oral breast-cancer franchise as a self-funding engine for a second drug. The June quarter is the first clean look at that claim: domestic demand for NERLYNX, the irreversible HER2 tyrosine kinase inhibitor sold as tablets, rose enough for management to lift full-year product and earnings ranges, while the Athyrium notes went to zero in early May. The equity now trades near the top of its fifty-two week range, which means the debt-free story and the demand rebound are no longer hidden. What is still open is whether that rebound is a durable patient-start recovery or a channel refill after a weak first quarter, and whether the cash the franchise throws off is enough to carry alisertib, the in-licensed Aurora kinase inhibitor, through a biomarker-selected late-stage path without another trip to the equity window.
The operating tension sits in the mix, not the headline. Product sales in the June quarter reached about $54 million, up from roughly $49 million a year earlier, and sequential growth from the first-quarter trough was even sharper once specialty-pharmacy demand and ex-factory bottles are lined up. Royalty income from overseas sub-licensees slipped a notch, so the total-revenue beat is almost entirely a United States story. Research spending rose as the ALISCA breast and lung studies expanded, which is why first-half net income still trails last year even though the June quarter itself was the strongest earnings print in the comparison set. Cash and marketable securities finished mid-year near $94 million after the final Athyrium remittance, and operating cash for the first six months stayed positive. The balance sheet is cleaner than it has been in years. The P and L is not yet a straight compounding machine.
The market is paying a high-teens trailing multiple and a mid-twenties forward multiple on a company that still describes itself as dependent on a single commercial product. That multiple is fair only if NERLYNX holds the new full-year product band near $207 million at the midpoint and if the fourth-quarter breast-study update keeps a registrational path open. The counterargument is straightforward: first-quarter destocking already showed how quickly bottles can disappear, diarrhea and later-line antibody-drug conjugates still cap duration, and composition-of-matter protection on neratinib runs only into the next decade. The next several prints decide whether Puma is a self-funded two-asset oncology story or a late-cycle cash cow whose second act remains optional.